Estimating the overall survival benefit of adjuvant chemo‐endocrine therapy in women over age 50 with pT1‐2N0 early stage breast cancer and 21‐gene recurrence score ≥26: A National Cancer Database analysis

Estimating the overall survival benefit of adjuvant chemo‐endocrine therapy in women over age 50 with pT1‐2N0 early stage breast cancer and 21‐gene recurrence score ≥26: A National Cancer Database analysis

Abstract Background Validation studies of the 21‐gene recurrence score (RS) previously demonstrated that adjuvant chemotherapy plus endocrine therapy (CET) was associated with a significant survival benefit in women with node negative breast cancer (BC) and RS >31. However, the TAILORx trial, did...

Full description

Bibliographic Details
Main Authors: Nickolas Stabellini, Lifen Cao, Christopher W. Towe, Amanda L. Amin, Alberto J. Montero
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Cancer Medicine
Subjects:
adjuvant chemotherapy
adjuvant endocrine therapy
breast cancer
ER +
overall survival
recurrence score
Online Access:https://doi.org/10.1002/cam4.6584

Similar Items

Similar Items